Sector Update: Health Care Stocks Stall Thursday; Invacare Falls to 20-Year Low Following Weak Q2 Results, CEO Retirement

By
A A A

Top Healthcare Stocks

JNJ +0.07%

PFE -0.03%


ABT +0.01%

MRK +0.19%

AMGN +0.11%

Healthcare stocks were narrowly lower today with the NYSE Healthcare Sector Index slipping about 0.2% and shares of healthcare companies in the S&P 500 also falling about 0.1% as a group.

In company news, Invacare Corp ( IVC ) slid to a 20-year low Thursday after the medical devices manufacturer posted a wider Q2 net loss and revenue trailing analyst expectations and said its chief executive officer will retire from the company next week.

IVC shares were off about 16% at $14.76 each, earlier falling to their lowest share price since July 1994 at $14.41 a share. Over the past 12 months, the stock has declined slightly less than 6% in value.

The company recorded a $0.36 per share net loss, exceeding the the Capital IQ consensus by $0.14 per share. Revenue declined 3.9% year over year to $331.3 million, also lagging estimates by around $3.45 million.

"Clearly, Invacare's businesses outside of Europe are under pressure and we are not pleased with the second quarter's consolidated financial results," CEO Gerald Blouch said in prepared remarks, adding the company is focused on improving free cash flow and restoring profitability in its North American and Asia/Pacific segments.

"We also are working to establish a new credit facility with our banks, as our existing credit facility matures in October 2015," Blouch said.

Separately today, IVC said Blouch will step down from the company on July 31 and will be replaced on an interim basis by Chief Financial Officer Robert Gunbranson.

In other sector news,

(+) SPNC, FDA approves the company's Turbo-Tandem and Turbo Elite peripheral laser atherectomy devices for treating in-stent restenosis.

(-) INCY, Reports 43.4% response rate among patients with polycythemia vera treated with its ruxolitinib drug candidate and a 29.6% response among patients treated with hydroxyurea, failing to produce a statistically significant reduction in symptoms.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.



This article appears in: Investing , Commodities

Referenced Stocks: IVC

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

What to Wear to a Wedding
What to Wear to a Wedding           
4th of July Outfits
4th of July Outfits                 

Stocks

Referenced

50%

Most Active by Volume

62,287,287
  • $17.03 ▼ 1.10%
26,194,993
  • $30.555 ▲ 1.24%
26,150,957
  • $126.44 ▼ 0.13%
25,197,634
  • $40.59 ▼ 6.26%
25,192,083
  • $19.07 ▲ 1.54%
24,563,617
  • $26.78 ▲ 0.45%
24,474,256
  • $5.85 ▲ 1.56%
24,111,132
  • $8.83 ▲ 2.08%
As of 7/2/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com